Skip to content
http://lifestyle.lmcordoba.com.ar/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
May 23, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
May 23, 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 22, 2026
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
May 21, 2026
/U P D A T E — Nuvation Bio Inc./
May 20, 2026
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
May 20, 2026
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
May 19, 2026
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
April 1, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 26, 2026
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
March 17, 2026
←
Previous Page
1
2
3
Next Page
→